Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
Autoimmunity Reviews|August 31, 2014
Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug?Ennio Giulio Favalli, Martina Biggioggero, Pier Luigi Meroni
Patient Related Outcome Measures|August 30, 2018
Sarilumab: patient-reported outcomes in rheumatoid arthritisChiara Crotti, Martina Biggioggero, Andrea Becciolini, et al.
Expert Review of Clinical Immunology|March 31, 2021
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemicEnnio Giulio Favalli, Gabriella Maioli, Martina Biggioggero, et al.
Biomed Research International|May 20, 2014
Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designsEnnio Giulio Favalli, Serena Bugatti, Martina Biggioggero, et al.
Clinical Reviews in Allergy & Immunology|January 25, 2013
Novel mechanisms of action of the biologicals in rheumatic diseasesCecilia Beatrice Chighizola, Ennio Giulio Favalli, Pier Luigi Meroni
Drug Design, Development and Therapy|December 28, 2018
Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selectionMartina Biggioggero, Chiara Crotti, Andrea Becciolini, et al.
Seminars in Arthritis and Rheumatism|December 17, 2013
The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysisEnnio Giulio Favalli, Francesca Pregnolato, Martina Biggioggero, et al.
Rheumatology (Oxford, England)|April 15, 2014
Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategiesEnnio Giulio Favalli, Martina Biggioggero, Antonio Marchesoni, et al.
Therapeutic Advances in Musculoskeletal Disease|August 4, 2012
The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trialsEnnio Giulio Favalli, Francesca Pregnolato, Martina Biggioggero, et al.
Drugs in Context|November 7, 2019
Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritisMartina Biggioggero, Andrea Becciolini, Chiara Crotti, et al.
Pageof 10